Discovery of structurally novel, potent and orally efficacious GPR119 agonists

被引：11

作者：

Alper, Phil ^{[1
]}

Azimioara, Mihai ^{[1
]}

Cow, Christopher ^{[1
]}

Mutnick, Daniel ^{[1
]}

Nikulin, Victor ^{[1
]}

Michellys, Pierre-Yves ^{[1
]}

Wang, Zhiliang ^{[1
]}

Reding, Esther ^{[1
]}

Paliotti, Michael ^{[1
]}

Li, Jing ^{[1
]}

Bao, Dingjiu ^{[1
]}

Zoll, Jocelyn ^{[1
]}

Kim, Young ^{[1
]}

Zimmerman, Matthew ^{[1
]}

Groessel, Todd ^{[1
]}

Tuntland, Tove ^{[1
]}

Joseph, Sean B. ^{[1
]}

McNamara, Peter ^{[1
]}

Seidel, H. Martin ^{[1
]}

Epple, Robert ^{[1
]}

机构：

[1] Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2014年 / 24卷 / 10期

关键词：

GPCR agonists; PR119; Pyrazolopyrimidines; Type; 2; diabetes; PROTEIN-COUPLED RECEPTOR; AGENTS;

D O I：

10.1016/j.bmcl.2014.03.023

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Screening hit 5 was identified in a biochemical screen for GPR119 agonists. Compound 5 was structurally novel, displayed modest biochemical activity and no oral exposure, but was structurally distinct from typical GPR119 agonist scaffolds. Systematic optimization led to compound 36 with significantly improved in vitro activity and oral exposure, to elevate GLP1 acutely in an in vivo mouse model at a dose of 10 mg/kg. (C) 2014 Elsevier Ltd. All rights reserved.

引用

页码：2383 / 2387

页数：5

共 11 条

[1]

[Anonymous], 2009, CURR OPIN DRUG DISCO, V12, P519

[2]

[Anonymous], 2011, EUR J MED CHEM, V46, P2901

[3] A role for β-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release [J].

Chu, Zhi-Liang ;

Jones, Robert M. ;

He, Hongmei ;

Carroll, Chris ;

Gutierrez, Veronica ;

Lucman, Annette ;

Moloney, Molly ;

Gao, Hui ;

Mondala, Helen ;

Bagnol, Didier ;

Unett, David ;

Liang, Yin ;

Demarest, Keith ;

Semple, Graeme ;

Behan, Dominic P. ;

Leonard, James .

ENDOCRINOLOGY, 2007, 148 (06) :2601-2609

[4] A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease [J].

Fisman, Enrique Z. ;

Tenenbaum, Alexander .

CARDIOVASCULAR DIABETOLOGY, 2009, 8

[5] GPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity [J].

Fyfe, Matthew C. T. ;

McCormack, James G. ;

Overton, Hilary A. ;

Procter, Martin J. ;

Reynet, Christine .

EXPERT OPINION ON DRUG DISCOVERY, 2008, 3 (04) :403-413

[6] The Emergence of GPR119 Agonists as Anti-Diabetic Agents [J].

Jones, Robert M. ;

Leonard, James N. .

ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 44, 2009, 44 :149-170

[7] GPR119 agonists for the treatment of type 2 diabetes [J].

Jones, Robert M. ;

Leonard, James N. ;

Buzard, Daniel J. ;

Lehmann, Juerg .

EXPERT OPINION ON THERAPEUTIC PATENTS, 2009, 19 (10) :1339-1359

[8] GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119 [J].

Kang, Sang-Uk .

DRUG DISCOVERY TODAY, 2013, 18 (23-24) :1309-1315

[9] New Drugs for Type 2 Diabetes Mellitus What is their Place in Therapy? [J].

Krentz, Andrew J. ;

Patel, Mayank B. ;

Bailey, Clifford J. .

DRUGS, 2008, 68 (15) :2131-2162

[10] Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents [J].

Overton, HA ;

Babbs, AJ ;

Doel, SM ;

Fyfe, MCT ;

Gardner, LS ;

Griffin, G ;

Jackson, HC ;

Procter, MJ ;

Rasamison, CM ;

Tang-Christensen, M ;

Widdowson, PS ;

Williams, GM ;

Reynet, C .

CELL METABOLISM, 2006, 3 (03) :167-175

← 1 2 →